CHF Solutions Announces 300% Increase in Utilization of Aquadex Therapy in NYC Hospitals, the Epicenter of COVID-19
April 16 2020 - 9:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload,
announced increased utilization of its Aquadex therapy in patients
affected by COVID-19. Product sales of the Aquadex therapy to six
hospitals in New York City, the epicenter of the pandemic in the
U.S., have increased over 300% in the last thirty days, as compared
to the monthly-average for 2019. The company is still evaluating
the impact the pandemic may have on its overall business.
Two physician-led webinars since the outbreak
have highlighted the importance of managing fluids administered to
critically ill, COVID-19 patients to avoid potentially
life-threatening complications, such as volume overload, acute
respiratory distress syndrome (ARDS), and other conditions related
to progressive congestion. Ultrafiltration with the Aquadex
SmartFlow™ system is an option for efficient fluid removal and
rapid decongestion, and a way to optimize the volume status of
these patients in a predictable way. Aquadex therapy has been used
as an alternative therapy in patients who need fluid removal when
dialysis machines or trained dialysis personnel are not available
and in hemodynamically unstable patients, who may not be able to
tolerate dialysis but still need fluid removal.
“Just a few weeks ago, we announced the first
use of Aquadex therapy in COVID-19 patients at hospitals in New
York and Georgia and increased our production to meet anticipated
demand. While this initial data involves only a handful of
hospitals that have experienced the first surges of patients, we
are very pleased to see that Aquadex therapy can help critically
ill patients during this pandemic,” said John Erb, CEO of CHF
Solutions. “We remain committed to supporting the dedicated medical
professionals through awareness, education and training about
treatment solutions for COVID-19 patients.”
About CHF Solutions CHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to improving the lives of patients suffering from fluid
overload with its novel ultrafiltration therapy system. The company
is focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow
System The Aquadex SmartFlow system delivers clinically
proven therapy using a simple, flexible and smart method of
removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow system is indicated for
temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the clinical use and expected
utilization of the Aquadex SmartFlow system in patients infected
with the coronavirus COVID-19. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our commercial strategy, the possibility that we may be unable to
raise sufficient funds necessary for our anticipated operations,
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. CHF Solutions does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024